43 completed, 4 unknown, 2 recruiting, 1 not yet recruiting. 50 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 50 | Completed 43, Unknown 4, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Unknown 1 |
Follow Encephalitis: new trials by email Literature Review of Encephalitis trials Research Report on Encephalitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy - Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Phase 3 | Recruiting | The First People's Hospital of Changzhou | 200 | 2024-11-08 | 2026-06-09 |
| Dexamethasone in Tick-borne Encephalitis Dexametasone, Saline (0.9% NaCl) - Tick-Borne Encephalitis | Phase 3 | Recruiting | University Medical Centre Ljubljana | 200 | 2024-05-03 | 2026-05-13 |
| Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection - Progressive Multifocal Leukoencephalopathy | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 33 | 2024-04-01 | 2024-02-26 |
| Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older TBE vaccine 0.5 mL, TBE vaccine 0.25 mL - Tick-Borne Encephalitis | Phase 3 | Completed | Pfizer | 165 | 2021-01-18 | 2023-11-22 |
| Dexamethasone in Herpes Simplex Virus Encephalitis Dexamethasone - HSV Encephalitis | Phase 3 | Unknown | University Hospital, Grenoble | 30 | 2018-11-01 | 2020-09-04 |
| Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam JEVAX, JECEVAX - Japanese Encephalitis | Phase 3 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 655 | 2017-09-30 | 2018-09-17 |
| Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis Immunoglobulins, Intravenous (Privigen), Placebo - Encephalitis | Phase 3 | Completed | University of Oxford | 18 | 2016-01-01 | 2024-03-04 |
| Purified Inactivated Japanese Encephalitis Vaccine Japanese Encephalitis Vaccine produced by IMBCAMS, Japanese Encephalitis Vaccine produced by Liaoning Chenda - Japanese Encephalitis Virus Disease | Phase 3 | Unknown | Chinese Academy of Medical Sciences | 1050 | 2015-09-01 | 2022-03-09 |
| Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) - Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 250 | 2015-06-01 | 2022-03-28 |
| New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly FSME-immune - Tick-borne Encephalitis | Phase 2 / Phase 3 | Completed | Sormland County Council, Sweden | 250 | 2015-01-01 | 2021-02-10 |
| A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants 0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine, 0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine, 0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) - Encephalitis | Phase 3 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 900 | 2014-10-01 | 2016-09-01 |
| Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea IMOJEV - Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 119 | 2013-07-11 | 2022-03-28 |
| Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Rabies, Japanese Encephalitis, Placebo - Rabies, Japanese Encephalitis | Phase 3 | Completed | Novartis Vaccines | 661 | 2012-08-01 | 2014-12-08 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis | 552 | 2011-11-01 | 2014-03-11 |
| Humoral Response to Tick-borne Encephalitis Vaccine in Elderly FSME-immune - Tick-borne Encephalitis | Phase 2 / Phase 3 | Completed | Sormland County Council, Sweden | 200 | 2011-09-01 | 2015-11-18 |
| Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers Live attenuated Japanese encephalitis chimeric virus vaccine, Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine) - Japanese Encephalitis, Japanese Encephalitis Virus Disease | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 274 | 2011-07-01 | 2014-04-25 |
| Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country IXIARO - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 300 | 2010-12-01 | 2014-12-19 |
| Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study Blood draw, IC51 has given in the parent study IC51-322 - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 23 | 2010-10-01 | 2020-03-18 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV JE-CV Vaccine, Varicella Vaccine - Japanese Encephalitis, Varicella | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 454 | 2010-08-25 | 2022-03-28 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus - Japanese Encephalitis, Measles | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 542 | 2010-08-01 | 2014-08-15 |
Showing 20 of 50. Sign in to see all of them.
Encephalitis, Japanese (32) · Encephalitis, Tick-Borne (10) · Rabies (2) · Anti-N-Methyl-D-Aspartate Receptor Encephalitis (1) · Autoimmune Diseases of the Nervous System (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Chickenpox (1) · Dengue (1) · Encephalitis, Herpes Simplex (1) · Encephalomyelitis (1) · Epilepsy (1) · Hepatitis A (1) · Herpes Simplex (1)
Brain Diseases (50) · Nervous System Diseases (50) · Neuroinflammatory Diseases (50) · Central Nervous System Diseases (49) · Infections (46) · Central Nervous System Viral Diseases (45) · Virus Diseases (45) · Central Nervous System Infections (44) · Encephalitis, Viral (44) · Infectious Encephalitis (44) · Arbovirus Infections (42) · Encephalitis, Arbovirus (42) · Flaviviridae Infections (42) · Flavivirus Infections (42) · RNA Virus Infections (42)
Japanese Encephalitis Vaccines (5) · Vaccines (4) · Blood Specimen Collection (2) · Hepatitis A Vaccines (2) · SA-14-14-2 vaccine (2) · Chickenpox Vaccine (1) · ChimeriVax (1) · Dexamethasone (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Immunization, Secondary (1) · Immunoglobulins (1) · Immunoglobulins, Intravenous (1) · Injections (1) · Measles Vaccine (1) · MenACWY-CRM vaccine (1)
Valneva Austria GmbH (13) · Sanofi Pasteur, a Sanofi Company (8) · Pfizer (7) · PATH (2) · Sanofi (2) · Sormland County Council, Sweden (2) · Assistance Publique - Hôpitaux de Paris (1) · Boryung Pharmaceutical Co., Ltd (1) · Chinese Academy of Medical Sciences (1) · Helsinki University Central Hospital (1) · Jiangsu Province Centers for Disease Control and Prevention (1) · London School of Hygiene and Tropical Medicine (1) · Mahidol University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Hygiene and Epidemiology, Vietnam (1)
Germany (9) · Austria (7) · Philippines (7) · United States (5) · Australia (4) · Poland (4) · Sweden (4) · Thailand (4) · China (3) · South Korea (3) · Czechia (2) · Finland (2) · France (2) · United Kingdom (2) · Vietnam (2)
Astrid Kaltenboeck, Ph.D. (3) · Andrea Ayad, Dr. (2) · Jerzy Brzostek, MD (2) · Jerzy Dziduch, MD (2) · Jerzy Romaszko, MD (2) · Krzysztof Sladek, MD (2) · Marian Patrzalek, MD (2) · Salvacion Gatchalian, MD (2) · Susanne Eder (2) · Susanne Eder, Mag. (2) · Andrew J Pollard, FRCPCH, PhD (1)
PMID 20934459, PMID 18394765, PMID 21288804, PMID 22696017, PMID 22777096, PMID 23967083, PMID 24656175, PMID 24717964, PMID 24873986, PMID 25308927, PMID 25483480, PMID 25567119, PMID 25956891, PMID 26005163, PMID 26994987, PMID 29081368, PMID 29325161, PMID 32156630, PMID 35101266, PMID 37945292, PMID 38614954, PMID 42293080
2008 (1), 2023 (1), N01AI30025 (1)